Predominance of healthcare-associated cases among episodes of community-onset bacteraemia due to extended-spectrum β-lactamase-producing Enterobacteriaceae.

Int J Antimicrob Agents

Medical Intensive Care Unit and Infection Control Unit, Henri Mondor University Hospital, APHP, Paris-Est Créteil University (UPEC), 51 Avenue du Maréchal de Lattre de Tassigny, 94000 Créteil, France. Electronic address:

Published: January 2017

Extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-PE) are endemic pathogens worldwide. Infection with ESBL-PE may be associated with inadequate antibiotic therapy and a poor outcome. However, risk factors for ESBL-PE community-acquired infections are ill-defined. An observational multicentre study was performed in 50 hospitals to identify the prevalence of and risk factors for community-acquired ESBL-PE bacteraemia. All patients presenting with community-onset Enterobacteriaceae bacteraemia were recorded over a 2-month period (between June and November 2013). Risk factors and 14-day outcomes of patients were investigated. Among 682 Enterobacteriaceae bacteraemia episodes recorded, 58 (8.5%) were caused by ESBL-PE. The most frequent species isolated were Escherichia coli (537; 76.7%) and Klebsiella spp. (68; 9.7%), of which 49 (9.1%) and 8 (11.8%), respectively, were ESBL-producers. Most ESBL-PE episodes were healthcare-associated, and only 22 (38%) were apparently community-acquired. The main risk factor for community-acquired ESBL-PE bacteraemia was a prior hospital stay of ≥5 days within the past year. The overall 14-day survival was 90%; only 4 (6.9%) of 58 patients with ESBL-PE bacteraemia died. Inadequate initial antibiotic therapy was administered to 55% of patients with ESBL-PE bacteraemia but was not associated with increased 14-day mortality. Although many patients had community-onset ESBL-PE bacteraemia, almost two-thirds of the episodes were actually healthcare-associated, and true community-acquired ESBL-PE bacteraemia remains rare. In our essentially non-severely ill population, inappropriate initial therapy was not associated with a higher risk of mortality.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijantimicag.2016.09.032DOI Listing

Publication Analysis

Top Keywords

esbl-pe bacteraemia
24
risk factors
12
community-acquired esbl-pe
12
esbl-pe
11
bacteraemia
9
extended-spectrum β-lactamase-producing
8
β-lactamase-producing enterobacteriaceae
8
antibiotic therapy
8
enterobacteriaceae bacteraemia
8
episodes healthcare-associated
8

Similar Publications

CTX-M, TEM, and SHV Genes in , and Isolated from Hematologic Cancer Patients with Bacteremia in Uganda.

Infect Drug Resist

February 2024

Department of Immunology and Molecular Biology, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda.

Purpose: We determined the phenotypic resistance to third-generation cephalosporins, phenotypic extended spectrum beta-lactamase (ESBL) prevalence, and genotypic prevalence of ESBL-encoding genes and in isolated from hematologic cancer patients with febrile neutropenia and bacteremia at the Uganda Cancer Institute (UCI).

Patients And Methods: Blood cultures from hematologic cancer patients with febrile neutropenia were processed in BACTEC 9120. and .

View Article and Find Full Text PDF

Predictors of mortality from extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia.

Emerg Microbes Infect

December 2023

Department of Medical Education and General Practice, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.

Article Synopsis
  • A systematic review and meta-analysis evaluated mortality predictors for patients with extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) bacteremia.
  • Among 4607 patients studied, a significant mortality rate of 21.2% was found, with specific factors like neutropenia and severe sepsis showing strong associations with increased mortality risk.
  • Conversely, prior appropriate antimicrobial therapy and urinary tract infections were identified as protective factors, highlighting the need for better management strategies for affected patients.
View Article and Find Full Text PDF

Objectives: Bloodstream infections (BSIs) caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) have become a worldwide public health threat, and beta-lactam/beta-lactamase inhibitor combinations (BLBLIs) are considered as one reliable carbapenem-sparing antibiotic. However, it is still controversial whether BLBLIs are truly noninferior to carbapenems. Therefore, we conducted this meta-analysis to compare the efficacy of BLBLIs with carbapenems for ESBL-PE BSIs.

View Article and Find Full Text PDF

This systematic review was conducted to compare the efficacy of non-carbapenem β-lactam/β-lactamase inhibitors (BLBLIs) versus carbapenems for the treatment of urinary tract infections (UTIs) caused by extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-PE). A comprehensive search of the Cochrane Library, PubMed and Embase was conducted from January 1979 to December 2020. Clinical success, microbiological success, clinical and microbiological success, and mortality were assessed as efficacy outcomes.

View Article and Find Full Text PDF

BackgroundAlgorithms for predicting infection with extended-spectrum β-lactamase-producing Enterobacterales (ESBL-PE) on hospital admission or in patients with bacteraemia have been proposed, aiming to optimise empiric treatment decisions.AimWe sought to confirm external validity and transferability of two published prediction models as well as their integral components.MethodsWe performed a retrospective case-control study at University Hospital Basel, Switzerland.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!